Long Term Outcomes of Intratympanic Dexamethasone in Intractable Unilateral Meniere’s Disease

  • Pradeep PradhanEmail author
  • Priti Lal
  • Kanwar Sen
Original Article


To evaluate the long term effect of Intratympanic dexamethasone in intractable Meniere’s disease. 30 patients with refractory Meniere’s disease which did not respond to the standard medical management, were treated with Intratympanic dexamethasone injections. Post treatment hearing outcome and dizziness scores were compared with the pretreatment values respectively. The mean dizziness handicap inventory (DHI) score was reduced from 91.58 (range 80–100) to be 31.00 (p = 0.00) at 3 months of treatment. With the successive follow-up periods, the mean DHI scores were reduced to 51.50, 46.6, and 50.90 at the end of, 6, 12, and 24 months (p = 0.04, 0.35, and 0.49 respectively). Again at the end of 24 months, 23.80% of patients were free of vertigo (p = 0.01). No patient had improvement in the hearing (> 10 dB) in any of the follow-up periods and 6.6% demonstrated deterioration in hearing. There were no major intraoperative or postoperative complications detected. Intratympanic injection of steroid is a safe and effective method for treating intractable Meniere’s disease. Although short term improvement in the vertigo is well documented, still in 23% of the patients were found to be free of vertigo at even the end of 24 months. There was no significant improvement in hearing noticed, either in short term or in long term.


Intractable Meniere’s disease Intratympanic dexamethasone Clinical outcomes 



This research has received no financial grant from any funding agency, commercial or not-for-profit sectors.

Compliance with Ethical Standards

Conflict of interest

The authors declare that there is no conflict of interest.


  1. 1.
    Atlas MD, Chai F, Boscata L (1998) Meniere’s disease. Evidence of an immune process. Am J Otol 19:628–631PubMedGoogle Scholar
  2. 2.
    Nagura M, Iwasaki S, Wu R, Mizuta K, Umemura K, Hoshino T (1999) Effect of corticosteroid contrast medium and ATP on focal microcirculatory disorders of the cochlea. Eur J Pharmacol 366:47–53CrossRefGoogle Scholar
  3. 3.
    Shirwany NA, Seidmann MD, Wenxue T (1998) Effect of transtympanic injection of steroids on cochlear blood flow, auditory sensitivity, and histology in the guinea pig. Am J Otol 19:230–235PubMedGoogle Scholar
  4. 4.
    Parnes LS, Sun A, Fremman DJ (1999) Corticosteroidpharmacokietics in the inner ear fluids: an animal study followed by clinical applications. Laryngoscope 109(Suppl 91):1–17CrossRefGoogle Scholar
  5. 5.
    Chandrashekhar SS, Rubinstein RY, Kwartler JA et al (2000) Dexamethasone pharmacokinetics in the inner ear: comparison of route of administration and use of facilitating agents. Otolaryngol Head Neck Surg 122:521–528Google Scholar
  6. 6.
    Silverstein H, Isaacson JE, Olds MJ, Rowan PT, Rosenberg S (1998) Dexamethasone inner ear perfusion for the treatment of Meniere’sdisease: a prospective, randomized, double-blind, crossover trial. Am J Otol 19:196–201PubMedGoogle Scholar
  7. 7.
    Casani AP, Piaggi P, Cerchiai N, Seccia V, Franceschini SS, Dallan I (2012) Intratympanic treatment of intractable unilateral Meniere disease: Gentamicin or dexamethasone? A randomized controlled trial. Otolaryngol Head Neck Surg 146:430–437CrossRefGoogle Scholar
  8. 8.
    Shea PF, Richey PA, Wan JY, Stevens SR (2012) Hearing results and quality of life after streptomycin/dexamethasone perfusion for Meniere’s disease. Laryngoscope 122:204–211CrossRefGoogle Scholar
  9. 9.
    Boleas-Aguirre MS, Lin FR, Della Santina CC, Minor LB, Carey JP (2008) Longitudinal results with intratympanic dexamethasone in thetreatment of Meniere’s disease. Otol Neurotol 29:33–38CrossRefGoogle Scholar
  10. 10.
    Weckel A, Marx M, Esteve-Fraysse MJ (2017) Control of vertigo in Ménière’s disease by intratympanic dexamethasone. Eur Ann Otorhinolaryngol Head Neck Dis 28(17):30112–30116Google Scholar
  11. 11.
    Shea PF, Richey PA, Wan JY, Stevens SR (2012) Hearing results and quality of life after streptomycin/dexamethasone perfusion for meniere’s disease. Laryngoscope 122:204–211CrossRefGoogle Scholar
  12. 12.
    Phillips JS, Westerberg B (2011) Intratympanic steroids for Ménière’s disease or syndrome. Cochrane Database Syst Rev 6(7):CD008514. CrossRefGoogle Scholar
  13. 13.
    Hu A, Parnes L (2009) Intratympanic steroids for inner ear disorders: a review. Audiol Neurotol 14:373–382CrossRefGoogle Scholar
  14. 14.
    Barrs DM (2009) Intratympanic steroid injections for intractable Meniere’s disease. Laryngoscope 111:2100–2104CrossRefGoogle Scholar
  15. 15.
    Arriaga MS, Goldman S (1998) Hearing results of intratympanic steroid injection treatment of endolymphatic hydrops. Laryngoscope 108:1682–1685CrossRefGoogle Scholar
  16. 16.
    Leng Y, Liu B, Zhou R, Liu J, Liu D, Zhang SL, Kong WJ (2017) Repeated courses of intratympanic dexamethasone injection are effective for intractable Meniere’s disease. Acta Otolaryngol 137(2):154–160CrossRefGoogle Scholar
  17. 17.
    Martin Sanz E, Zschaeck C, Gonzalez M, Mato T, Rodrigañez L, Barona R, Sanz R (2013) Control of vertigo after intratympanic corticoid therapy for unilateral Ménière’s disease: a comparison of weekly versus daily fixed protocols. Otol Neurotol 34(8):1429–1433CrossRefGoogle Scholar
  18. 18.
    Hamid MA (2001) Intratympanic dexamethasone perfusion in Menieres disease. In: Presented at the spring meeting of the American Neurotology society, Palm Desert CA, p 12Google Scholar

Copyright information

© Association of Otolaryngologists of India 2018

Authors and Affiliations

  1. 1.Department of OtorhinolaryngologyAll India Institute of Medical SciencesBhubaneswarIndia
  2. 2.Department of OtorhinolaryngologySafdarjung Hospital & Vardhmann Mahavir Medical CollegeNew DelhiIndia
  3. 3.Department of OtorhinolaryngologyDr. RML HospitalNew DelhiIndia
  4. 4.Department of ENT and Head Neck SurgeryAll India Institute of Medical SciencesBhubaneswarIndia

Personalised recommendations